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Monthly access flow monitoring with increased prophylactic
angioplasty did not improve fistula patency.
Background. Regular access monitoring is recommended to
detect and treat access stenosis in order to prevent access throm-
bosis and failure.
Methods. In 1999, we instituted monthly access blood flow
monitoring using the ultrasound dilution technique (UDT). In
a sequential observational trial, 222 patients were studied for
the impact of UDT monitoring on patency of their first arte-
riovenous autogenous fistula. Group 1, the historic group (be-
fore 1999), had 146 arteriovenous fistulas (50.7% upper arm),
followed for 259 access-years. Group 2, the UDT-monitored
group, had 76 arteriovenous fistulas (60.5% upper arm), fol-
lowed for 123 access-years. Decision to refer for angiography
was based on clinical criteria for group 1, and clinical criteria
plus results of UDT flow monitoring in group 2.
Results. Cumulative patency was longer (P < 0.01) and the
thrombosis rate was lower (P < 0.05) in group 2. However, the
improvement occurred prior to initiation of UDT flow moni-
toring. Comparing outcomes in group 2 patients whose fistula
survived to start flow monitoring with group 1 patients whose
fistula survived at least 160 days (the median time to starting
UDT monitoring in group 2), there was a sevenfold increase
in angioplasty procedures (0.67 vs. 0.09 per access-year) but
no improvement in the thrombosis rate or cumulative fistula
patency.
Conclusion. UDT monitoring increased the rate of angio-
plasty procedures and thereby shortened primary unassisted
patency, but did not decrease the thrombosis rate or improve
cumulative fistula patency.
Vascular access failure is a common cause of morbid-
ity and engenders substantial cost in caring for patients
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on chronic hemodialysis. The most common underlying
cause of access failure is venous neointimal hyperplasia
leading to access stenosis and thrombosis [1]. A number
of studies have shown that access monitoring using non-
invasive tests such as intra-access pressure, access flow
rate, or duplex ultrasound examination can detect the
presence of stenosis before it leads to thrombosis [2–
7]. In addition, early prospective observational studies
found that regular access monitoring to detect and treat
stenosis could decrease the rate of access thrombosis and
might prolong access patency [2–4, 8]. Based on these
studies, in 1997, the clinical practice guidelines from the
National Kidney Foundation-Dialysis Outcomes Quality
Initiative (K/DOQI) recommended that regular access
surveillance be done to detect and treat access stenosis
[9]. Since then, much effort has been devoted to defining
the best monitoring approach and to determine whether
such an approach when combined with early intervention
to treat stenosis can not only decrease the rate of throm-
bosis but also improve cumulative access patency. In this
regard, two recent randomized prospective studies have
found that the addition of regular blood flow monitoring
or duplex ultrasound to routine access surveillance did
not improve cumulative access patency in patients with
arteriovenous grafts [10, 11]. In addition, early correc-
tion of graft stenosis prior to thrombosis was not found
to improve overall graft patency compared to observa-
tion and correction after thrombosis [12]. The situation
may be different for native fistulas. A recent prospective
controlled trial did find that prophylactic angioplasty of
stenosis prolonged the time to fistula thrombosis or sur-
gical revision when compared to observation without in-
tervention [13]. However, a thrombosed native fistula can
be salvaged and cumulative patency prolonged [14] but
this was not reported in the study by Tessitore et al [13].
Hence, it remains unknown whether prophylactic repair
of stenotic lesions will improve cumulative access patency
in fistulas.
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Based on the K/DOQI recommendations, in 1999,
we initiated a program of regular monthly access blood
flow monitoring using the ultrasound dilution technique
(UDT) to detect and treat access stenosis before it re-
sulted in thrombosis and failure. Because the majority
of our dialysis patients have a native fistula [15], blood
flow monitoring was chosen as the monitoring technique
of choice [5]. A highly trained technician performed the
access flow measurements but the attending nephrolo-
gist for each patient made the ultimate access manage-
ment decisions. The expectation was that the addition of
the prospective UDT surveillance program onto usual
care would improve cumulative fistula patency. The goal
of the present longitudinal prospective study was to test
this expectation by comparing access outcomes during
the 4.25 years of access monitoring with access outcomes
in the immediate preceding 7 years. Data on access pa-
tency in this earlier, nonflow monitored group of subjects
has been previously published [15].
METHODS
Study setting
The study was conducted at a single-center in a
university-based teaching hospital. Over the 11-year ob-
servation, seven staff surgeons accounted for 77% of all
access surgeries and six staff radiologists accounted for
85% of the interventional radiology procedures.
Vascular access database
A prospective database of all vascular access creations
and procedures was established in 1991 and maintained
by dialysis unit staff. The characteristics of this database
were described in a previous publication [15]. The charts
for all patients entered since the last systematic review of
this database in 1999 was completed were reviewed and
the database updated and validated.
Study design
This was a longitudinal observational study comparing
access outcomes in patients who received a new arteri-
ovenous autogenous fistula and underwent regular access
flow monitoring during the 4.25 years from January 1999
to March 2003 (group 2) to access outcomes in historic
control patients who received a new autogenous fistula
during the preceding 7 years (1992 to 1998) and did not
undergo access flow monitoring (group 1). For patients
in group 2, each month the results of the monthly ac-
cess blood flow measurement (Qa) was provided to the
attending nephrologist along with a graph showing ac-
cess blood flows over the preceding year and the per-
cent change in access blood flow from baseline (Qa)
for each patient. Flow monitoring was provided as an
adjunct to usual access monitoring practices and the at-
tending physician was ultimately responsible for the fi-
nal decisions regarding access management. Usual access
monitoring practices over the entire period of the study
typically consisted of reviewing the dynamic venous and
arterial pressures, monthly adequacy of dialysis (Kt/V),
access recirculation as well as clinical symptoms and ex-
amination. Prior to the advent of regular blood flow mon-
itoring access recirculation was measured by the urea
technique with a value greater than 10% recirculation
being considered abnormal. During the flow-monitoring
era, the urea technique was supplanted by measurement
of recirculation by the UDT with a value greater than 0%
considered abnormal.
Access blood flow measurement
Access flow measurements were performed by the
saline-infusion UDT using the Transonic Hemodialysis
Monitor (HD01) (Transonic Systems, Inc., Ithaca, NY,
USA) with dual flow/dilution sensors [16]. Every attempt
was made to get the measurements done between 30 and
120 minutes after starting dialysis. Access recirculation
was measured first with the hemodialysis blood flow lines
in the normal configuration for dialysis. The arterial and
venous lines were then reversed, the dialyzer pump set
to a blood flow of 200 mL/min and ultrafiltration turned
off for measurement of access blood flow. Two measure-
ments of blood flow were made at each visit for every
patient. If the measurements varied by more than 10%,
then a third measurement was performed and the results
were averaged to obtain the monthly access blood flow
(Qa). Preliminary studies in our unit had shown that mea-
surement of access blood flow by UDT correlated closely
with independent measurement of access blood flow by
Doppler ultrasound done on a nondialysis day by a radi-
ologist who was blinded to the results of the UDT flow
measurement (slope = 0.98; r2 = 0.91).
Monitoring algorithm
To help establish an algorithm for using flow monitor-
ing data, there was a short 10-month prestudy observation
period prior to January 1999 in which flow monitoring
was done but the data was not provided to the dialy-
sis physicians nor used for access management. During
this prestudy, a total of 321 monthly flow measurements
were obtained on 42 subjects (nine grafts and 33 fistulas).
All access events (i.e., thrombosis, angioplasty, or surgery
for stenosis) were recorded and linked to the preceding
monthly flow measurement. Figure 1 shows the number
of flow measurements and the probability of an access
event at each flow rate. Based on this data and the avail-
able literature, we elected to use a flow rate of less than
600 mL/min or a cumulative drop in flow rate more than
25% from baseline as an indication for access evaluation
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Fig. 1. Probability of an adverse access event
within 1 month of the reported ultrasound di-
lution technique (UDT) measured flow rate.
These data were collected during a 10-month
prestudy observation period prior to January
1999, in which UDT flow monitoring was per-
formed but the data were not provided to
the dialysis physicians nor used to direct ac-
cess management. A total of 321 monthly flow
measurements were obtained on 42 subjects
(nine grafts and 33 fistulas). All access events
(i.e., thrombosis, angioplasty, or surgery for
stenosis) were recorded and linked to the pre-
ceding monthly flow measurement. The solid
line shows the percent probability of an ad-
verse event; the bars represent the number of
measurements at each UDT measured flow.
for grafts. However, when analyzing the data separately
for fistulas, it appeared that a significant increase in ac-
cess events did not occur until 200 mL/min (not shown).
After discussion with the dialysis physicians and consid-
eration that the desired blood flow rate for dialysis was
400 mL/min, then the parameters to refer a native fistula
for evaluation were set at 450 mL/min or less or a 25%
drop in flow below the baseline.
Endovascular intervention
A fistula referred for angiography was evaluated for
stenosis using digital subtraction angiography (DSA) in
at least two orthogonal views. Entry into the access was
usually obtained in an antegrade manner in the segment
adjacent to the arteriovenous anastomosis. Retrograde
cannulation was obtained from the downstream segment
to visualize the arterial anastomosis. Reflux into the arte-
rial anastomosis was routinely accomplished by manual
compression of the outflow. Any stenosis deemed hemo-
dynamically significant and amenable to intervention un-
derwent immediate percutaneous transluminal balloon
angioplasty. A bolus of 3000 units of heparin was given
prior to the procedure. Angioplasty of the stenotic seg-
ment(s) was performed in the standard manner using an
appropriately sized balloon catheter (balloon diameter
chosen to be 10% to 15% greater than the diameter of
the adjacent normal vein). The balloon was inflated to 10
to 12 atmospheres pressure for 30 to 60 seconds. Repeated
inflations and/or higher inflation pressure balloons were
used for resistant stenoses. The goal of the intervention
was to dilate the stenotic segment to a residual stenosis of
≤30%. In the presence of clot, thrombus was cleared prior
to angioplasty using a combination of techniques, includ-
ing mechanical thrombectomy devices, balloon macera-
tion, and suction thrombectomy and/or pharmacologic
thrombolysis.
Data coding and outcome measures
Patients in group 1 had a new fistula placed from 1992
to 1998 and did not have the results of monthly UDT flow
monitoring to make access decisions. Patients in group 2
had a new fistula placed from 1999 to March 2003 and
had monthly UDT flow monitoring. The UDT monitor-
ing started in most patients during the first month that
the fistula was cannulated by two needles for dialysis.
Primary unassisted patency was defined as the time from
fistula placement to the first access event (e.g., thrombo-
sis, angioplasty, surgery, or access failure for any reason)
excluding a diagnostic angiogram or ultrasound test. Cu-
mulative patency was defined as fistula patency from the
time of placement to ultimate failure of the fistula regard-
less of how many procedures it took to maintain patency.
A fistula was determined to have thrombosed if it failed
without other explanation (e.g., ligation for ischemia) or
if a procedure was needed to remove thrombus at the
time of access intervention. Angioplasty done at the time
of thrombolysis or thrombectomy was not coded as a
separate procedure. Patient diagnoses came from cross
correlation with patient billing records. UDT flow moni-
toring did not start until a median of 160 days after fistula
surgery. To determine the direct effect of UDT flow mon-
itoring on fistula patency, we analyzed primary unassisted
patency and cumulative patency in each patient in group
2 both before and after the actual start date of UDT mon-
itoring. For patients in group 1 we used the median start
of UDT flow monitoring of 160 days to generate similar
patency data to compare with group 2.
Statistical analysis
Data were analyzed using S-Plus 6 (Insightful Corp.,
Seattle, WA, USA). Nominal variables were compared
using the chi-square statistic. Continuous variables were
expressed as mean ± SEM and compared using analysis
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of variance (ANOVA). Thrombosis and angioplasty rates
were calculated for each patient by dividing the number
of thrombosis or angioplasty events by the duration of cu-
mulative access patency in years. However, the distribu-
tion of these individual thrombosis and angioplasty rates
was highly skewed and not amenable to standard statis-
tic analysis (e.g., Poisson regression). Most patients had
no thrombotic or angioplasty event, while a few patients
had numerous events over a relatively short access sur-
vival. The data are presented graphically by plotting the
cumulative distribution function (CDF), the cumulative
probability of having a thrombosis or angioplasty rate at
or below a given value. The curves were compared us-
ing the Kolmogorov-Smirnov test. The angioplasty and
thrombosis data was further evaluated by the time to
first event using the Kaplan-Meier analysis with different
groups compared by the log-rank statistic. Analyses that
reached significance (P < 0.05) were considered statisti-
cally significant. Relative risk was determined using the
Cox proportional hazards model and the 95% confidence
limits are reported. For comparison to other literature re-
ports we also calculated population thrombosis and an-
gioplasty rates by dividing the total number of events by
the total number of years of access follow-up and this
metric is presented in the results.
Fistula patency was analyzed using the Kaplan-Meier
method with different groups compared by the log-rank
statistic. In the primary analysis, fistula patency was cal-
culated from the day of fistula creation and censored for
patient death, transfer to another dialysis unit or to an-
other mode of renal replacement therapy. For the analy-
sis of fistula patency before initiation of flow monitoring
then access patency was calculated from the date of fistula
creation and censored at the start of access monitoring
(group 2) or at 160 days (group 1) as well as for death or
transfer to another unit or to another modality of renal
replacement therapy. For analysis of fistula patency after
initiation of flow monitoring then only fistulas that re-
mained patent at the start of access monitoring (group 2)
or at 160 days (group 1) were included in the analysis. In
this latter analysis, fistula patency was calculated as start-
ing at the time of flow monitoring (group 2) or 160 days
(group 1) and censored as done for the primary analysis.
Covariates for fistula patency were analyzed using a Cox
proportional hazards model. In this model, all nominal
patient demographic and comorbidity data were coded
as either present or absent. The continuous variables age
and body mass index were analyzed as linear variables.
Data for individual surgeons were analyzed separately
except that surgeons who did less than 10 total accesses
in the database were grouped together as a single group.
The distribution of access flow rates was skewed. There-
fore, log-transformed flow rates were used to normalize
the data and ANOVA was used to compare the effect of
Table 1. Baseline characteristics of group 2 [ultrasound dilution
technique (UDT) monitored) and group 1 (controls) at time of first
arteriovenous fistula placement.
Group 1 Group 2 P value
Number 146 76
Upper arm% 50.7 60.5
Age years 54.9 ± 1.5 57.6 ± 1.7
Body mass index kg/m2 25.9 ± 0.5 28.0 ± 0.9 0.03
White% 92.5 89.5
Female% 42.5 40.8
Hypertension% 99.3 100
Diabetes% 49.3 56.6
Coronary vascular disease% 52.7 68.4 0.02
Peripheral vascular disease% 39 52.6 0.05
Hyperlipidemia 43.8 60.5 0.02
Surgeon A% 32.2 17.1
Surgeon B% 20.6 0
Surgeon C% 11.6 0
Surgeon D% 5.5 29.0
Surgeon E% 0 22.4
Surgeon F% 6.9 0
Surgeon G% 0 18.4
Surgeon H% 23.3 13.2
Comparative statistics for each surgeon were not specifically reported but
overall surgical input was different between the two groups.
angioplasty on the log-transformed flow rate. The level
of significance was set at P < 0.05 for all analyses.
RESULTS
This report focuses on subjects who got an autogenous
fistula as their first arteriovenous access. At our center,
an autogenous fistula was the predominant first access for
all patients (72% in group 1) and tended to increase in
group 2 (80%) (P = NS). Table 1 shows the baseline char-
acteristics of group 1, the historic control subjects who re-
ceived their first arteriovenous fistula between 1992 and
1998 and did not undergo flow monitoring compared to
group 2 subjects who received their first fistula between
1999 and March 2003 and underwent monthly access flow
monitoring. The study populations were similar in aver-
age age, race, and gender. An increased body mass in-
dex and the presence of documented diabetes, vascular
disease and the diagnosis of hyperlipidemia were more
common in group 2 compared to group 1. Staff surgeons
who supervised fistula placement did evolve over time
and were different between the two groups.
Information on the time from access placement to first
hemodialysis and in those patients who had a catheter,
from first hemodialysis to catheter removal is shown in
Table 2. There was a nonsignificant trend toward ear-
lier placement of the fistula prior to first hemodialysis
in group 2. Approximately 50% of patients in each group
had a catheter and in those patients the catheter remained
in longer in group 2 compared to group 1. Also shown in
Table 2 is the time when UDT flow monitoring starts rel-
ative to access placement, first hemodialysis and catheter
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Table 2. Comparison of access management patterns in group 1 and group 2
Access placement Hemodialysis to Access placement Hemodialysis to first Catheter removal to
to first catheter removal to first ultrasound ultrasound dilution first ultrasound dilution
hemodialysis days days dilution technique days technique days technique days
Group 1 86 ± 26 (37) 71 ± 9 (58)
Group 2 113 ± 30 (57) 141 ± 26 (86)a 228 ± 27 (160) 124 ± 15 (106) −15 ± 24 (16)
The table shows the time (days) from access placement to the first recorded hemodialysis session and in those patients who had a catheter, the time from first
hemodialysis to catheter removal (or access failure if that preceded catheter removal). In addition, for group 2 the time from access placement first hemodialysis or
catheter removal to first ultrasound dilution technique (UDT) flow measurement is shown. Catheters were used in 47% of group 1 patients and 51% of group 2 patients.
The data are reported as mean ± SEM with the median shown in parentheses. A negative value for time between catheter removal and UDT monitoring indicates that
monitoring began before catheter removal.
aP < 0.05 between the group 1 and group 2 by analysis of variance (ANOVA).
removal. UDT flow monitoring started around the time
of catheter removal (mean 15 ± 24 days before catheter
removal or median 16 days after catheter removal) indi-
cating that flow monitoring began shortly after the access
was fully usable for dialysis.
Initiation of a monthly flow-monitoring program was
found to increase the overall rate of angioplasty pro-
cedures (population angioplasty rate per fistula year in
group 1, 0.10, and in group 2, 0.58). As demonstrated by
the cumulative distribution function shown in Figure 2A,
only 11% of patients in group 1 had any angioplasty pro-
cedure compared to over 45% in group 2. By Kaplan-
Meier analysis, the time to first angioplasty procedure was
significantly shorter in group 2 (relative risk by Cox pro-
portional hazards model 4.47, 95% confidence limits 2.43
to 8.66). There was also a numerical decrease in the over-
all population thrombosis rate in group 2 (thrombosis per
fistula-year in group 1, 0.26, and in group 2, 0.21). Analysis
of these results as shown in Figure 2B demonstrated that
fewer people in group 2 suffered any thrombosis (23% in
group 2 compared to 33% in group 1) and the cumulative
distribution function for thrombosis for group 2 was sig-
nificantly less than group 1. There were a small number
of patients in both groups (about 7% in group 2 and 13%
in group 1) that had a very high rate of thrombosis due to
a fistula that clotted rapidly within the first 3 to 6 months
after surgical placement. The time to first thrombosis was
also significantly delayed in group 2 compared to group 1
(relative risk by the Cox proportional hazards model 0.39,
95% confidence limits 0.16 to 0.82).
Figure 3 shows the analysis of fistula patency in the
two groups. Overall there was no difference in primary
unassisted patency between the two groups. Cumulative
patency was significantly better in group 2 compared to
group 1. Univariate analysis using the Cox proportional
hazards model with the covariates listed in Table 1 re-
vealed that only patient group and the type of fistula (up-
per arm compared to forearm) significantly influenced
cumulative access patency. Patient group remained an
important predictor of cumulative access patency even
after multivariate analysis accounting for access type and
surgeon (Table 3). Overall, these results suggested a pos-
sible benefit of flow monitoring and angioplasty to de-
crease fistula thrombosis and prolong fistula patency.
However, UDT flow monitoring does not start until
the patient is using the new fistula for dialysis. As shown
in Table 2, the median time from access surgery to the
first access flow measurement was 160 days (Fig. 3, dot-
ted lines). Closer inspection of the curves for primary
unassisted patency (Fig. 3A) reveals a sharp drop in fis-
tula patency in the flow-monitored group (group 2) after
about 180 days, followed by a crossover and reversal in the
fistula patency curves for the two groups. The explanation
for the rapid decrease in primary unassisted patency in
group 2 was the increased rate of angioplasty procedures
that occur with access flow monitoring.
To explore this further, we analyzed the angioplasty
rate, the thrombosis rate, and fistula patency before and
after the actual date of initiation of flow monitoring in
group 2 and compared this to fistula patency in group 1
before and after 160 days (the median time of starting
UDT flow measurements in group 2). The highest rate of
thromboses in both groups occurred shortly after fistula
placement before the onset of access monitoring (data
not shown). After the onset of flow monitoring the angio-
plasty rate increased in group 2 but not in group 1 and was
sevenfold higher than the rate of angioplasty procedures
in group 1 after 160 days (group 2, 0.67; group 1, 0.09
procedures per access-year). This is shown graphically
using the cumulative distribution function in Figure 4B,
where both the percent of patients that had any angio-
plasty as well as the rate of angioplasties per patient was
markedly increased in group 2 compared to group 1. The
time to first angioplasty was also significantly faster in
group 2 (relative risk by Cox proportional hazards 4.92,
95% confidence limits 2.46 to 10.5). However, despite the
increased number of angioplasty procedures the overall
thrombosis rate was not different in group 2 compared
to group 1 after starting flow monitoring. As shown in
Figure 4A, only 14% of people in either group had any
thrombosis and there was no difference in the cumula-
tive distribution function or the time to first thrombosis
(relative risk by Cox proportional hazards 0.99, 95% con-
fidence limits 0.2 to 4.17) between the two groups.
Shahin et al: Monthly access ﬂow monitoring failed to improve ﬁstula patency 2357
100
90
80
70
60
50
Cu
m
ul
at
ive
 p
ro
ba
bi
lity
Group 1
Group 2
0 5 10 15 20
Thrombosis rate, number/access-yr
A
100
90
80
70
60
50
Cu
m
ul
at
ive
 p
ro
ba
bi
lity
Group 1
Group 2
0 1 2 3 4 5 6 7 8
Angioplasty rate, number/access-yr
B
Fig. 2. Cumulative distribution function for thrombosis and angio-
plasty rates. The graph plots the cumulative probability of having a
thrombosis or angioplasty rate at or below the rate shown on the hor-
izontal access. The thrombosis (A) and angioplasty (B) rates are ex-
pressed as number of events per access-year per patient starting from
the time of fistula placement until fistula failure, death, transplant, or
transfer out of the unit or the end of the study. The thrombosis rates
were higher in group 1 compared to group 2. However, only 23% of
group 2 and 33% of group 1 patients had any thrombosis over the life of
their fistula. Angioplasty was done in nearly four times as many patients
in group 2 compared to group 1. Note that the cumulative probability
axis is truncated at 0.5 for thrombosis (A) and angioplasty (B). Using
the Kolmogorov-Smirnov test, the cumulative distribution function for
group 1 compared to group 2 is different for angioplasty rate (P < 0.001)
and thrombosis rate (P = 0.024).
As suggested by Figure 3, survival analysis using access
patency data prior to initiation of UDT flow monitoring
(or 160 days in group 1) demonstrated that both primary
unassisted patency and cumulative patency were signifi-
cantly better in group 2 (P < 0.01 for both analyses) (data
not shown). Also, as expected based on the increased
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Fig. 3. Primary unassisted patency and cumulative patency. The results
represent primary unassisted patency (A) and cumulative patency (B)
for the first arteriovenous fistula starting from the time of fistula cre-
ation. Note the crossover between the two curves for primary patency
after 160 days (vertical dotted line) that represents the median time of
starting ultrasound dilution technique (UDT) flow monitoring in group
2. Primary unassisted patency was not different and cumulative access
patency was significantly better in group 2 compared to historic control
patients (group 1). The same results are seen when all arteriovenous
accesses are combined or when restricted to just grafts.
angioplasty rate, primary unassisted patency decreased
in group 2 after initiation of flow monitoring (Fig. 5A).
However, there was no difference in cumulative access
patency between the two groups (Fig. 5B). Correcting
for differences in baseline covariates listed in Table 1 by
the use of the Cox proportional hazards model did not
change these results (not shown). Specifically the rela-
tive risk for cumulative patency after the start of UDT
flow monitoring was 1.0 (95% confidence limits 0.39 to
2.38) for group 1 compared to group 2.
The access patency data were also examined for all ac-
cesses combined regardless of whether they were a graft
or fistula or the first access placed (N = 322 in group 1
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Table 3. Cox proportional hazards analysis of covariates for
cumulative access patency
RR (95% CI) P value
Group 2 vs. group 1 0.46 (0.26-0.78) 0.003
Lower arm fistula vs. upper arm 1.3 (1.01-1.60) 0.03
Surgeon 1.08 (0.99-1.17) 0.07
All covariates shown in Table 1 were included in the analysis and only the
covariates shown in Table 3 reached statistical significance. After correcting for
measured covariates, patients in group 2 still had a significantly lower risk of
access failure compared to group 1 control patients.
and 119 in group 2) and separately for all grafts (N =
118 in group 1 and 34 in group 2). The results for both pri-
mary unassisted patency as well as cumulative patency for
all accesses combined were exactly the same as reported
above for first accesses. In addition, subgroup analysis
limited to just grafts gave the same results as shown
above for first fistulas with one exception. For grafts, there
was no difference in primary unassisted patency between
group 2 and group 1 prior to the start of UDT flow moni-
toring. However, the same decrease in primary unassisted
patency as well as no benefit for cumulative patency after
the start of UDT flow monitoring was observed.
To assess the efficacy of angioplasty to treat stenosis
and improve access flow we examined the UDT measured
flow rates before and after angioplasty. For all accesses in
the flow-monitored group the very first UDT measured
flow rate was 1107 ± 59 mL/min. The first UDT mea-
sured flow rate for those patients who subsequently had
an angioplasty was 924 ± 86 mL/min (N = 43) (NS com-
pared to the entire group). Prior to the first angioplasty,
the flow rate had dropped to 624 ± 65 mL/min (P < 0.01
compared to initial flow). Following angioplasty the flow
rate increased to 833 ± 78 mL/min (P < 0.05 compared
to preangioplasty) (NS compared to first flow). For all
angioplasties combined the preangioplasty flow rate was
507 ± 34 mL/min and the postangioplasty flow rate was
739 ± 39 mL/min (N = 98) (P < 0.05 compared to pre-
angioplasty flow rate).
DISCUSSION
The principal finding of this study is that despite an in-
crease in the rate of prophylactic angioplasty procedures
the initiation of monthly access flow monitoring did not
improve cumulative fistula patency compared to histori-
cal controls. Primary unassisted patency decreased as a
consequence of the increased rate of angioplasty pro-
cedures after initiating UDT monitoring. Based on the
measured flow rates immediately before and after an-
gioplasty, the angioplasty intervention was effective at
largely restoring flow to its original baseline level. Cor-
recting for differences in baseline covariates between the
two groups did not change these results. Similar results
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Fig. 4. Cumulative distribution function for thrombosis and angio-
plasty rates after initiation of ultrasound dilution technique (UDT) flow
monitoring. The data are plotted as described for Fig. 2. The thrombosis
(A) and angioplasty (B) rates are expressed as number of events per
access-year per patient starting from when UDT monitoring was initi-
ated (group 2) or 160 days after fistula creation (group 1) until fistula
failure, death, transplant, or transfer out of the unit or the end of the
study. There was no difference in the thrombosis rate between the two
groups. Angioplasty was done in more patients and more frequently
in group 2 compared to group 1. Note that the cumulative probability
axis is truncated at 0.5 for thrombosis (A) and angioplasty (B). Using
the Kolmogorov-Smirnov test, the cumulative distribution function for
group 1 compared to group 2 is different for angioplasty rate (P < 0.005)
but not for thrombosis rate (P = NS).
were also found when we included all arteriovenous ac-
cesses in the analysis.
The present results are consistent with recent random-
ized controlled trials that failed to show a benefit of
regular access flow monitoring or preemptive interven-
tion on cumulative patency of arteriovenous grafts [10–
12]. However, our results differ from prior prospective
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Fig. 5. Primary unassisted patency and cumulative patency after initi-
ation of ultrasound dilution technique (UDT) flow monitoring. The re-
sults represent primary unassisted patency (A) and cumulative patency
(B) for the first arteriovenous fistula starting from the initiation of UDT
monitoring (group 2) or 160 days after fistula creation (group 1). Pri-
mary unassisted patency was significantly worse and cumulative fistula
patency was not different in patients who received monthly UDT flow
monitoring (group 2) compared to historic control patients (group 1).
The same results are seen when all arteriovenous accesses are combined
or when restricted to just grafts.
observational studies that demonstrated a benefit of rou-
tine access monitoring to reduce thrombosis rates and
suggested that monitoring may improve access patency
[2–4, 8, 17, 18]. Our results also appear to conflict with
a recent randomized controlled study showing that pro-
phylactic correction of access stenosis in a native fistula
delays access thrombosis compared to observation with
no intervention [13]. However, in the latter study, it was
not reported whether the thrombosed fistula could be sal-
vaged and whether cumulative patency was prolonged by
angioplasty. One explanation for these differences is that
there may be a baseline rate of angioplasty beyond which
access patency is not improved. For instance, a study by
Besarab et al [4] in a population predominated by pros-
thetic grafts, showed an inverse correlation between the
rate of angioplasty procedures and access thrombosis up
to 0.3 angioplasty procedures per patient-year. In con-
trast, our fistula-predominant historic control group with
usual monitoring had an overall rate (including both fistu-
las and grafts) of 0.16 angioplasty procedures per patient-
year that was increased to 0.77 angioplasty procedures
per patient-year in group 2 during UDT monitoring. Sim-
ilarly, in the study by Moist et al [11] looking at prosthetic
grafts, the baseline rate of angioplasty procedures (0.61
per patient-year) was high and patency did not improve
when the rate of angioplasty increased to 0.93 per patient-
year in the monitored group. Hence, there may be an
upper limit on the rate of preemptive angioplasty pro-
cedures (at least with current techniques) beyond which
access survival is not prolonged. The optimal rate of an-
gioplasty procedures is not known and likely depends on
many factors including the type and location of the access
and length of time from access creation [19].
This study raises the question, why earlier detection
and prophylactic treatment of stenosis that produced a
documented improvement in access flow rates did not
improve cumulative access patency? It has been reported
that some stenotic lesions in fistulas do not progress [20]
and thus we might have been dilating lesions that would
not have lead to access failure. This seems unlikely, how-
ever, because on average there was a significant drop
in flow rate that preceded the intervention suggesting
that the lesions were progressive and hemodynamically
significant. This is further underscored by the study of
Tessitore et al [13] demonstrating that fistulas with steno-
sis that were not dilated ultimately went on to failure. A
more likely explanation for our results is that angioplasty,
while effective at temporarily dilating the stenosis, also
incites inflammatory events that hasten restenosis and ul-
timate access failure [21]. Consistent with this notion is
the observation that the duration of access patency tends
to decrease and the intimal proliferation index tends to
increase with each successive angioplasty procedure [21,
22]. There is variability however in the restenosis rate with
some patients achieving a long-term secondary patency
after angioplasty. This suggests that there are patient-
related or procedure-related variables that influence the
response to angioplasty and that angioplasty may signif-
icantly prolong access survival in some patients but may
also shorten survival in others.
This study found that adding flow monitoring to usual
access monitoring did not improve cumulative fistula pa-
tency. Fistulas are more resistant to thrombosis even at
low flow rates. Hence, it may be that traditional less sen-
sitive methods of detecting access stenosis (e.g., access
examination, arterial and venous pump pressures, inabil-
ity to achieve adequate blood flow rate, low Kt/V, access
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recirculation, excessive access bleeding, arm swelling) are
sufficient to detect and correct stenosis in a fistula before
it leads to access failure. Given the ability of fistulas to
tolerate a lower flow rate and the potential limitations
of early angioplasty, the addition of UDT flow monitor-
ing to detect stenosis at an earlier stage may not have
significant benefit in this population. This should not be
interpreted to mean that K/DOQI guidelines for routine
access monitoring in patients with fistulas is not beneficial
or that initiating UDT flow monitoring in a unit that does
not have a monitoring program would not improve ac-
cess survival. However, careful regular attention to clini-
cal criteria for fistula dysfunction and prompt referral for
angiography and angioplasty may be adequate for fistu-
las. There remains a need to define the optimum, most
efficient and cost effective means to monitor accesses to
prevent thrombosis and prolong access survival.
This study has limitations. We used historic rather than
concurrent controls and the study was not randomized,
thus there is a risk of uncontrolled bias. For instance,
changes in access management practices such as the trend
toward increased upper arm fistulas or surgical expertise
or better preoperative vascular mapping may explain why
our primary and cumulative fistula patency prior to initia-
tion of UDT monitoring was better in group 2 than group
1. This increase in early patency was seen despite the fact
that group 2 tended to be older, with more vascular dis-
ease and diabetes. However, despite the improvement in
early fistula patency, there was no difference in cumu-
lative patency after starting UDT monitoring. Although
there was a slight increase in the percent of upper arm
fistulas in group 2, it seems unlikely that this would have
mitigated the benefit of angioplasty. Subgroup analysis of
cumulative fistula survival did not show any difference in
the cumulative patency of either upper arm or lower arm
fistulas in group 2 after starting UDT monitoring when
compared to group 1 after 160 days (data not shown).
Moreover, correcting for differences in the other vari-
ables shown in Table 1 did not uncover an effect of group
on cumulative fistula survival after start of UDT monitor-
ing. There is an increasing trend to salvage thrombosed
fistulas [14] and we observed that some thrombosed fistu-
las were salvaged in this study. We do not know whether
the effort to salvage thrombosed fistulas in the two groups
was different but if the effort to salvage thrombosed fis-
tulas was greater in group 2 then this might have been
expected to improve cumulative patency. An additional
source of bias is that fistulas in group 2 appeared to take
longer to mature than in group 1 (as reflected by longer
catheter utilization shown in Table 2). Arguments can be
made that this would bias either for or against a benefi-
cial effect of flow monitoring in group 2 but none of the
arguments seemed uniquely persuasive. However, there
was an important bias in the selection of the “start point”
(i.e., left censoring) for the analysis of the effect of flow
monitoring. All fistulas included in group 2 were func-
tional by virtue of being selected for undergoing UDT
flow monitoring and the “start point” was determined by
the initiation of UDT flow monitoring. The “start point”
in group 1 was set at a fixed time point (160 days) after
access placement and some fistulas may not have been
functional at this time and therefore had a higher base-
line risk of failure. This bias favors a better outcome in
group 2. However, this concern is mitigated by the fact
that fistulas in group 1 appeared to mature and be used
faster than in group 2. Moreover, the hazard rate for both
groups was constant after starting UDT monitoring (or
160 days in group 1) so changing the “start point” by
60 days would not have changed the outcome.
Ultimately, a randomized controlled trial would be
needed to confirm whether the addition of frequent flow
monitoring or another standardized access monitoring
technique to routine clinical parameters would improve
fistula survival. Given the results of the present study,
there would be no ethical barriers to performing such a
study. However, such a study would require more than
1000 subjects enrolled over 3 years with a 2-year follow-
up to have an 80% power to detect a 25% improvement
in cumulative fistula survival with access monitoring as-
suming no dropouts or crossover. Hence, it would be very
difficult to do such a study in a timely manner within a
single dialysis center.
The population thrombosis rate for fistulas (0.26 per
fistula-year) in group 1 is higher than that reported as the
baseline rate in other recent studies [17, 18, 23]. This is due
to the high rate of thrombosis and access loss that occurs
shortly after access creation. Most prior studies have used
subjects already on dialysis (thus excluding the high rate
of early post-surgical fistula thrombosis). The comparable
baseline rate in our study would be 0.08 events per fistula-
year in group 1 subjects who still had their fistula 160 days
after surgical creation. This baseline rate is similar to the
lower thrombosis rate seen in other studies after starting
monitoring. Hence, it might have been difficult to show an
improvement in thrombosis rate in our population with
additional monitoring.
CONCLUSION
We found that adding regular monthly UDT flow mon-
itoring onto usual access monitoring increased the rate of
angioplasty procedures but did not reduce the thrombo-
sis rate or prolong cumulative access patency. The rea-
son why earlier detection of access stenosis and more
frequent angioplasty did not improve cumulative access
patency needs to be explored. There remains a need to de-
fine the optimum, most efficient, and cost effective means
to detect and treat access stenosis with the goal of pre-
venting thrombosis and prolonging access survival.
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